Background Blood-based methods using cell-free DNA (cfDNA) are under development as
an alternative to existing screening tests. However, early-stage detection of cancer using …

Background High tumor mutational burden (TMB) is an emerging biomarker of sensitivity to
immune checkpoint inhibitors and has been shown to be more significantly associated with …

Therapeutic antibodies blocking programmed death-1 and its ligand (PD-1/PD-L1) induce
durable responses in a substantial fraction of melanoma patients. We sought to determine …

Events that occur in the early fetal environment have been linked to long-term health and
lifespan consequences in the adult. Intrauterine growth restriction (IUGR), which may occur as …

The homeostatic control of blood pressure hinges upon the delicate balance between
prohypertensinogenic and antihypertensinogenic systems. D 1 -like dopamine receptors […

Engineered bacterial cells that are designed to express therapeutic enzymes under the
transcriptional control of remotely inducible promoters can mediate the de novo conversion of …

105 Background: Agents blocking programmed death-1/ligand (aPD1) induce durable
responses in many melanoma patients (pts). Greater numbers of somatic mutations have been …

• Blood-based tests hold great promise as cancer diagnostics, but most current tests are
restricted to the analysis of a single class of molecules (eg, circulating tumor DNA, circulating …

Blood-based markers can be used to non-invasively predict cancer progression after treatment.
Here, cell-free DNA (cfDNA) and plasma proteins were evaluated to explore biological …

Introduction: Bacterial cytosine deaminase (CD) mediates the de novo conversion of the non-toxic
prodrug, 5-fluorocytosine (5-FC) to its cytotoxic form, 5-fluorouracil (5-FU). Enzyme …